Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GRN | P28799 | 4/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250642 | 0.84 | LMNA (0.47) | LMNAKDM4EAPAF1POLBGRN | |
| SCHEMBL30970919 | 0.84 | GAA (0.49) | LMNAKDM4EAPAF1POLBGRN | |
| SCHEMBL22857792 | 0.82 | GAA (0.46) | LMNAKDM4EPOLBMAPTHTT | |
| SCHEMBL23115836 | 0.81 | KDM4E (0.51) | LMNAKDM4EAPAF1POLBGRN | |
| SCHEMBL3614239 | 0.81 | KDM4E (0.51) | LMNAKDM4EAPAF1POLBGRN | |
| SCHEMBL23138330 | 0.81 | SMN1; SMN2 (0.45) | LMNAKDM4EPOLBMAPTALDH1A1 | |
| SCHEMBL710008 | 0.80 | MAPT (0.56) | LMNAKDM4EAPAF1POLBGRN | |
| SCHEMBL2518853 | 0.80 | HCAR3 (0.45) | LMNAKDM4EAPAF1POLBGRN | |
| SCHEMBL4754841 | 0.80 | KDM4E (0.50) | LMNAKDM4EAPAF1POLBGRN | |
| SCHEMBL14097078 | 0.79 | LMNA (0.68) | LMNAKDM4EAPAF1POLBGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113631228-B | Macrocyclic compounds as STING agonists | 鲁宾有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220144852-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS | LUPIN LIMITED (IN) | 2022-05-12 | — | — | US | disclosed |
| US-20220144852-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS | LUPIN LIMITED (IN) | 2022-05-12 | — | — | US | disclosed |
| EP-3946610-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS | Lupin Limited (IN) | 2022-02-09 | — | — | EP | disclosed |
| CN-113631228-A | Macrocyclic compounds as STING agonists | 鲁宾有限公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-3848366-A1 | HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2021-07-14 | — | — | EP | disclosed |
| CN-110016021-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| WO-2021052501-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2021-03-25 | — | — | WO | disclosed |
| WO-2021000770-A1 | HETEROCYCLIC COMPOUND CAPABLE OF ENHANCING IMMUNE ACTIVITY, PREPARATION METHOD THEREFOR AND APPLICATION IN MEDICINE | 凯复制药有限公司 | 2021-01-07 | — | — | WO | disclosed |
| WO-2020194160-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS | LUPIN LIMITED (IN) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020194160-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS | LUPIN LIMITED (IN) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020042995-A1 | HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND | 杭州阿诺生物医药科技有限公司 | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | STING1, CGAS, MYD88 | LMNA 3488/4885KDM4E 3353/4885APAF1 1367/4885 |
| US-20220144852-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS | STING1, CGAS, TBK1 | LMNA 1710/4885KDM4E 4074/4885APAF1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.